Drugs / YH22189
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02608242 | Nov 2015 → Jun 2016 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH22189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02608242 ↗ |
| Route | Oral | “All subjects will receive a single oral dose of YH22189 FDC or telmisartan/amlodipine or rosuvastatin administered in the morning on Day 1.” NCT02608242 ↗ |